Evidence map›Paper›PMID 38457194›Full record

ReviewJournal of clinical microbiology2024

Cefazolin as a predictor of urinary cephalosporin activity in indicated Enterobacterales.

Alexandra L Bryson, Amira Bhalodi, Rachael M Liesman, Amy J Mathers

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Alexandra L BrysonDepartment of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.ORCID 0000-0002-2957-7829
Amira BhalodiScientific and Medical Affairs Consulting, Newton, Pennsylvania, USA.
Rachael M LiesmanDepartment of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Amy J MathersDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health, Charlottesville, Virginia, USA.
Medical College of Wisconsin · USScientific Consulting Group · USUniversity of Virginia · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditionally, cephalothin susceptibility results were used to predict the susceptibility of additional cephalosporins; however, in 2013-2014, the Clinical and Laboratory Standards Institute (CLSI) revisited this practice and determined that cefazolin is a more accurate proxy than cephalothin for uncomplicated urinary tract infections (uUTIs). Therefore, a cefazolin surrogacy breakpoint was established to predict the susceptibility of seven oral cephalosporins for

Indexed as

CefazolinUrinary Tract InfectionsAnti-Bacterial AgentsCephalosporinsCephalothinEscherichia coliHumansMicrobial Sensitivity TestsMonobactamsAnti-Bacterial AgentsCefazolinCephalosporinsCephalothinMonobactamsantimicrobial susceptibility testingbreakpointscefazolincefazolin surrogateoral cephalosporinsuncomplicated UTIurinary tract infectionUTI

Identifiers

PMID38457194
PMCPMC11005412
OpenAlexW4392600679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.